{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T18:08:02Z","timestamp":1787162882690,"version":"build-2736575974"},"reference-count":23,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.autrev.2020.102622","type":"journal-article","created":{"date-parts":[[2020,7,12]],"date-time":"2020-07-12T01:44:41Z","timestamp":1594518281000},"page":"102622","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Towards a novel target therapy for renal diseases related to plasma cell dyscrasias: The example of AL amyloidosis"],"prefix":"10.1016","volume":"19","author":[{"given":"Dario","family":"Roccatello","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Fenoglio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Baldovino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Naretto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Ferro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Barreca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Savino","family":"Sciascia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2020.102622_bb0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102495","article-title":"Clinical associations ofrenal involvement in ANCA-associated vasculitis","author":"Kronbichler","year":"2020","journal-title":"Autoimmun Rev"},{"issue":"10","key":"10.1016\/j.autrev.2020.102622_bb0010","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/j.autrev.2017.07.015","article-title":"\u201cHow I treat\u201d autoimmune diseases: state of the art on themanagement of rare rheumatic diseases and ANCA-associated systemic idiopathicvasculitis","volume":"16","author":"Roccatello","year":"2017","journal-title":"Autoimmun Rev"},{"issue":"5","key":"10.1016\/j.autrev.2020.102622_bb0015","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.autrev.2019.03.003","article-title":"Free light chains and autoimmunity","volume":"18","author":"Napodano","year":"2019","journal-title":"Autoimmun Rev"},{"issue":"2","key":"10.1016\/j.autrev.2020.102622_bb0020","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.autrev.2018.08.006","article-title":"Th17 cells in renal inflammation and autoimmunity","volume":"18","author":"Dolff","year":"2019","journal-title":"Autoimmun Rev"},{"issue":"2","key":"10.1016\/j.autrev.2020.102622_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2019.102450","article-title":"Autoantigenomics: holistic characterization of autoantigen repertoires for abetter understanding of autoimmune diseases","volume":"19","author":"Moritz","year":"2020","journal-title":"Autoimmun Rev"},{"issue":"8","key":"10.1016\/j.autrev.2020.102622_bb0030","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.autrev.2017.05.016","article-title":"Survivin in autoimmune diseases","volume":"16","author":"Gravina","year":"2017","journal-title":"Autoimmun Rev"},{"issue":"1","key":"10.1016\/j.autrev.2020.102622_bb0035","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.autrev.2012.07.017","article-title":"Attempts at suppression of amyloidogenesis in a mouse model by a variety of anti-inflammatory agents","volume":"12","author":"Shtrasburg","year":"2012","journal-title":"Autoimmun Rev"},{"issue":"9","key":"10.1016\/j.autrev.2020.102622_bb0040","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/j.autrev.2018.03.014","article-title":"Pathogenic role of tissue-resident memory T cells in autoimmune diseases","volume":"17","author":"Wu","year":"2018","journal-title":"Autoimmun Rev"},{"issue":"3","key":"10.1016\/j.autrev.2020.102622_bb0045","doi-asserted-by":"crossref","first-page":"102469","DOI":"10.1016\/j.autrev.2020.102469","article-title":"Understanding the immunopathogenesis of autoimmune diseases by animal studiesusing gene modulation: a comprehensive review","volume":"19","author":"Lee","year":"2020","journal-title":"Autoimmun Rev"},{"issue":"2","key":"10.1016\/j.autrev.2020.102622_bb0050","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1182\/blood-2016-01-629790","article-title":"What is new in diagnosis and management of light chain amyloidosis?","volume":"128","author":"Palladini","year":"2016","journal-title":"Blood"},{"issue":"76","key":"10.1016\/j.autrev.2020.102622_bb0055","doi-asserted-by":"crossref","first-page":"10664","DOI":"10.1039\/C8CC04396E","article-title":"Immunoglobulin light chain amyloid aggregation","volume":"54","author":"Blancas-Mejia","year":"2018","journal-title":"Chem Commun (Camb)"},{"issue":"6","key":"10.1016\/j.autrev.2020.102622_bb0060","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.2215\/CJN.02740806","article-title":"Light-chain (AL) amyloidosis: diagnosis and treatment","volume":"1","author":"Sanchorawala","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"issue":"22","key":"10.1016\/j.autrev.2020.102622_bb0065","doi-asserted-by":"crossref","first-page":"4448","DOI":"10.1182\/blood.V128.22.4448.4448","article-title":"Improved survival in AL amyloidosis: a population-based study on 1,430 patients diagnosed in Sweden 1995-2013","volume":"128","author":"Weiss","year":"2016","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.autrev.2020.102622_bb0070","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1007\/s12325-015-0250-0","article-title":"Light chain amyloidosis: patients experience survey from the amyloidosis research consortium","volume":"32","author":"Lousada","year":"2015","journal-title":"Adv Ther"},{"issue":"1","key":"10.1016\/j.autrev.2020.102622_bb0075","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1080\/13506129.2019.1672650","article-title":"The utility of repeat kidney biopsy in systemic immunoglobulin light chain amyloidosis","volume":"27","author":"Angel-Korman","year":"2019","journal-title":"Amyloid"},{"issue":"3","key":"10.1016\/j.autrev.2020.102622_bb0080","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1002\/ajh.21948","article-title":"Changes in serum-free light chain rather than intact monoclonal immunoglobulin levels predicts outcome following therapy in primary amyloidosis","volume":"86","author":"Kumar","year":"2011","journal-title":"Am J Hematol"},{"issue":"2","key":"10.1016\/j.autrev.2020.102622_bb0085","doi-asserted-by":"crossref","first-page":"110","DOI":"10.3109\/13506120309041732","article-title":"Phenotypic analysis of plasma cells in bone marrow using flow cytometry in AL amyloidosis","volume":"10","author":"M","year":"2003","journal-title":"Amyloid"},{"key":"10.1016\/j.autrev.2020.102622_bb0090","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.3389\/fimmu.2018.02722","article-title":"CD38: a target for immunotherapeutic approaches in multiple myeloma","volume":"9","author":"Morandi","year":"2018","journal-title":"Front Immunol"},{"issue":"Supplement 1","key":"10.1016\/j.autrev.2020.102622_bb0095","article-title":"Safety, tolerability and response rates of Daratumumab in patients with relapsed light chain (AL) amyloidosis: results of a phase II study","volume":"132","author":"Sanchorawala","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2020.102622_bb0100","article-title":"Extended follow-up and organ responses with Daratumumab therapy in previously treated AL amyloidosis","volume":"2019","author":"Chung","year":"2019","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.autrev.2020.102622_bb0105","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s00380-010-0019-y","article-title":"Association between clinical characteristics and AL amyloid deposition in the kidney","volume":"25","author":"Itabashi","year":"2010","journal-title":"Heart Vessels"},{"issue":"18","key":"10.1016\/j.autrev.2020.102622_bb0110","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1182\/blood.2019004369","article-title":"A prospective phase II of daratumumab in previously treated systemic light chain amyloidosis patients","volume":"135","author":"Roussel","year":"2020","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.autrev.2020.102622_bb0115","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1007\/s00262-018-2140-1","article-title":"Daratumumab augments alloreactive natural killer cell cytotoxicity towards CD38+ multiple myeloma cell lines in a biochemical context mimicking tumour microenvironment conditions","volume":"67","author":"Mahaweni","year":"2018","journal-title":"Cancer Immunol Immunother"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997220301890?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997220301890?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T21:20:23Z","timestamp":1761600023000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997220301890"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":23,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["S1568997220301890"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2020.102622","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Towards a novel target therapy for renal diseases related to plasma cell dyscrasias: The example of AL amyloidosis","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2020.102622","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102622"}}